Notice2026-09244

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
May 11, 2026

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 90 (Monday, May 11, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 90 (Monday, May 11, 2026)]
[Notices]
[Pages 25582-25583]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-09244]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2025-N-2220]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Testing 
Communications On Medical Devices and Radiation-Emitting Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the 
collection of information by June 10, 2026.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be submitted to <a href="https://www.reginfo.gov/public/do/PRAMain">https://www.reginfo.gov/public/do/PRAMain</a>. Find this particular information 
collection by selecting ``Currently under Review--Open for Public 
Comments'' or by using the search function. The OMB control number for 
this information collection is 0910-0678. Also include the FDA docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Amber Barrett, Office of Operations, 
Food and Drug Administration, Three White Flint North, 10A-12M, 11601 
Landsdown St., North Bethesda, MD 20852, 301-796-8867, 
<a href="/cdn-cgi/l/email-protection#b9e9ebf8eacdd8dfdff9dfddd897d1d1ca97ded6cf"><span class="__cf_email__" data-cfemail="653537243611040303250301044b0d0d164b020a13">[email&#160;protected]</span></a>.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Testing Communications On Medical Devices and Radiation-Emitting 
Products

OMB Control Number 0910-0678--Extension

    FDA is authorized by section 1003(d)(2)(D) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 393(d)(2)(D)) to conduct educational 
and public information programs. FDA must conduct needed research to 
ensure that such programs have the highest likelihood of being 
effective. Improving communications by FDA's Center for Devices and 
Radiological Health (CDRH) involves many research methods, including 
individual in-depth interviews, mall-intercept interviews, focus 
groups, self-administered surveys, gatekeeper reviews, and omnibus 
telephone surveys.
    The information collected will serve three major purposes. First, 
as formative research it will provide critical knowledge needed about 
target audiences to develop messages and campaigns about product use. 
Knowledge of consumer, caregiver, and healthcare professional decision-
making processes will provide a better understanding of target 
audiences that FDA needs to design effective communication strategies, 
messages, and labels.
    Second, as initial testing, the collected information will allow 
FDA to assess the potential effectiveness of messages and materials in 
reaching and successfully communicating with intended audiences. 
Testing messages with a sample of the target audience will allow FDA to 
refine messages while still in the developmental stage. Respondents 
will be asked to give their reaction to the messages in either 
individual or group settings.
    Third, as evaluative research, the collected information will allow 
FDA to ascertain the effectiveness of the messages and the distribution 
method in achieving the objectives of the message campaign. Evaluation 
of message campaigns is a vital link in continuous improvement of 
communications at FDA.
    FDA expects to conduct studies under this generic information 
collection using a variety of research methods. We

[[Page 25583]]

estimate that the burden to respondents will average 16 minutes each 
(varying from 5 minutes to 90 minutes). FDA estimates the burden of 
this collection of information based on prior experience with the 
various types of data collection methods described earlier.
    In the Federal Register of August 7, 2025 (90 FR 38155), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    FDA estimates the burden of this collection of information as 
follows:

                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                  Number of       Total
           Activity               Number of     responses per     annual       Average burden per    Total hours
                                 respondents     respondent     responses           response
----------------------------------------------------------------------------------------------------------------
Individual In-Depth                       420               1          420  0.75 (45 minutes)......          315
 Interviews.
General Public Focus Group                288               1          288  1.50...................          432
 Interviews.
Intercept Interviews: Central             200               1          200  0.25 (15 minutes.......           50
 Location.
Intercept Interviews:                   4,000               1        4,000  0.08 (5 minutes).......          320
 Telephone.
Self-Administered Surveys....           2,400               1        2,400  0.25 (15 minutes)......          600
Gatekeeper Reviews...........             400               1          400  0.50 (30 minutes)......          200
Omnibus Surveys..............           1,200               1        1,200  0.17 (10 minutes)......          204
                              ----------------------------------------------------------------------------------
    Total (General Public)...           8,908  ..............  ...........  .......................        2,121
----------------------------------------------------------------------------------------------------------------
Healthcare Professional                    72               1           72  0.75 (45 minutes)......           54
 Individual In-Depth
 Interviews.
Healthcare Professional Focus             144               1          144  1.50...................          216
 Group Interviews.
                              ----------------------------------------------------------------------------------
    Total (Healthcare                     216  ..............  ...........  .......................          270
     Professionals).
                              ----------------------------------------------------------------------------------
    Total (Overall)..........           9,124  ..............  ...........  .......................        2,391
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Based on a review of the information collection since our last 
request for OMB approval, we have made no adjustments to our burden 
estimate.

Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-09244 Filed 5-8-26; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on May 11, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.